USFDA9 Oct 2026, 08:15 pm
Rubicon Research: US FDA inspects Satara facility, issues 1 observation
AI Summary
Rubicon Research Ltd announced that the US FDA conducted an unannounced inspection of its manufacturing facility in Satara, Maharashtra, from October 5-9, 2026. The inspection resulted in one observation, which the company described as procedural and not related to data integrity. Rubicon is confident in working with the regulator to resolve the observation. This inspection follows successful unannounced US FDA inspections of its Toronto and Pithampur facilities in FY2026-27, and a recent inspection of its newly acquired US facility. The company will provide further updates as necessary.
Key Highlights
- US FDA inspected Rubicon's Satara manufacturing facility.
- One procedural observation was issued by the US FDA.
- Observation is not related to data integrity.
- Company confident in timely resolution with regulator.
- This is the third successful unannounced US FDA inspection for the company in FY2026-27.
Price Impact
More from RUBICON